LILLY
Who’s left running Nvidia? Inside the boardroom that pushed out Jensen Huang
After concerns regarding personal conduct, Jensen Huang has stepped down as president and CEO of Nvidia, leading to unrest among employees who support him. Many team members have voiced their opinions through social media and internal channels, while an internal survey shows a notable demand for his reinstatement. The board now faces mounting pressure to identify an appropriate successor in light of this sudden exit.
US Stock Market today: S&P 500, Nasdaq fall ahead of Nvidia earnings report, Anthropic IPO. List of Wall Street stocks that rise on Friday
S&P 500, Nasdaq's losses came ahead of AI company Anthropic's much-anticipated IPO next week. Nvidia is scheduled to announce earnings report on next Tuesday, November 17.
Who is Indian-origin Aarti Shah, who decided Jensen Huang’s fate along with other Nvidia board members?
Jensen Huang has stepped down as the CEO of Nvidia after a long tenure of 33 years. Colette Kress, the chief financial officer, will be acting as the interim CEO during this transition. The board of directors is now involved in the search for Huang's permanent successor. Here's a look at Indian-origin board member Aarti Shah and the other directors involved in the company's leadership transition.
Ozempic Zepbound eye risk warnings: Diabetes, weight-loss drugs Novo Nordisk's Ozempic, Wegovy, Eli Lilly's Mounjaro, Zepbound pose potential threat to eye, sudden vision loss, warns US FDA
Eli Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy were under scanner of United States Food and Drug Administration (US FDA).
Between the chip and the slip: Honeytrap suspicions further sours ties between US and China
Nvidia's CEO Jensen Huang is being investigated for having an alleged affair with a potential Chinese intelligence agent. This individual reportedly sought to gather information about Nvidia's advanced technology. Nvidia's board has launched an independent probe to examine the allegations against Huang. US lawmakers are demanding a briefing on the matter amid heightened concerns over national security.
US Stock Market today: Why are S&P 500, Dow Jones, Nasdaq down? Check top and worst performing stocks at Wall Street
Wall Street today saw one of the shocking losses as Google-parent Alphabet sufferedthe worst day since the company began trading at the US Stock Market.
- Go To Page 1

US Markets Today: US stocks end lower as Alphabet revenue miss revives AI capex jitters
Wall Street ended the day on a sour note, as Alphabet's revenue shortfall cast a shadow over the AI investment landscape and overall market stability. The Nasdaq Composite was hardest hit, plummeting by 1.36 percent. Although the economy shows robust growth, investor focus shifted to inflation numbers and corporate profitability, which displayed resilience.

US stocks today: Nasdaq slides over 1% as Alphabet's AI spending revives investor concerns
The Nasdaq Composite dropped over 1% as Alphabet reported disappointing advertising results. The downturn was worsened by software stocks, which fell following Fortinet and ServiceNow's unfavorable quarterly performances. Rising AI spending concerns and inflation data also impacted investor sentiment. On a brighter note, Eli Lilly's shares surged due to strong revenue forecasts, while Caterpillar faced declines as it kept its annual sales forecast steady.

Cipla expects US business to draw support from upcoming product pipeline
Cipla reported a significant decline in its consolidated net profit for the second quarter of FY27. The company's North American revenue fell by 19% due to increased competition impacting sales of generic Revlimid. However, Cipla anticipates that its upcoming product pipeline will support performance in North America. In India, domestic revenue rose, providing some resilience amidst challenges in the US market.

AI halves drug discovery times, but =trial bottleneck remains a costly reality
Novo Nordisk, Sanofi and Dr Reddy’s Laboratories are among the companies exploring applications ranging from drug discovery to laboratory automation and research.

From Carnegie to Claude: AI wealth could reshape philanthropy
A wave of American wealth created by artificial intelligence companies could produce some of the largest charitable sums since the era of Andrew Carnegie and John D. Rockefeller, raising questions about where the money goes. Nan Ransohoff of payments firm Stripe has described the moment as a "third wave" of American philanthropy, after the industrial fortunes of the late 19th century and the internet billionaires of recent decades.

US stocks face crucial test as AI earnings, Fed meeting loom
US stocks face a crucial week as earnings from Alphabet, Microsoft and Amazon coincide with the Federal Reserve’s policy decision. Investors will assess whether massive AI investments can deliver sustainable returns, while the Fed’s guidance on interest rates and uncertainty surrounding the November midterm elections could shape market sentiment and volatility.

US Stock Market prediction: S&P 500, Nasdaq, Dow Jones look to rebound as Wall Street investors set to be driven by a few factors, top stocks to follow
US Stock Market today: Investors also have their focus trained on the US midterm elections on November 3, with growing bets that the Democrats will wrest control of the US Congress away from President Donald Trump's Republican party.

Wall Street Week Ahead: Earnings flood, Fed meeting will test rickety AI market rally
US stock investors are on the edge of their seats as they anticipate quarterly earnings from tech giants like Alphabet, Microsoft, and Amazon. This week is pivotal, with the Federal Reserve meeting also in sight, likely to shape how investors feel about the AI sector. After disappointing earnings from firms such as Meta and Lam Research, mixed sentiment looms over the market, especially with the midterm elections on the horizon.

5 world market themes for the week ahead
An important week is upcoming with central banks like the Federal Reserve and European Central Bank making policy decisions. Major companies, including Alphabet, Amazon, and Microsoft, are set to report their earnings. Political events are also significant, with elections in Israel and Brazil influencing markets. China's leadership will hold discussions focused on party governance amidst external pressures.

GLP-1 boom in China, India, Brazil could create $22 billion market by 2035, J.P. Morgan says
The China-India-Brazil market for GLP-1 weight-loss drugs could expand to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan estimates. Improving affordability, generic launches and wider access could drive adoption, though penetration remains low, particularly in India, where cost concerns and cultural resistance to injectable treatments remain key barriers.

Ozempic wave boosts US cobblers and tailors as Americans tighten their belts
Consumers in the US are experiencing significant changes in their wardrobes due to weight-loss medications. Many individuals are opting for alterations instead of purchasing new clothing items. This trend is impacting various services, including cobblers and tailors. Discount stores and thrift shops are also benefiting from the rise in GLP-1 drug users. As clothing sizes fluctuate, many people seek more affordable wardrobe options while adjusting to their new sizes.

Beauty firms chase 'Ozempic face' market as weight-loss drugs boom
Galderma, Natura, and L'Oreal are developing treatments for consumers experiencing facial sagging due to rapid weight loss. These companies are responding to increased demand linked to the popularity of GLP-1 obesity drugs. Experts indicate that rapid weight loss may lead to skin laxity and diminished facial volume. While existing treatments show promise, some limitations remain in addressing deeper facial structure issues.

US stocks today: US stocks end higher as healthcare stocks lift Dow, tech a breather
Wall Street ended higher on Tuesday, led by the Dow as investors shifted towards healthcare and other value stocks. The S&P 500 also gained, while the Nasdaq slipped as technology stocks paused after a rebound in the previous session. Healthcare shares gained, while small-caps and defensive sectors also outperformed.

US stocks today: US stocks gain as healthcare stocks hit record high, oil prices fall
Wall Street's main indexes saw increases driven by a rally in healthcare stocks that reached record highs. Easing oil prices contributed to a recovery from the previous week's technology led selloff. Major companies like General Motors and Steel Dynamics reported disappointing earnings forecasts, while 3M and Equifax exceeded expectations. Investors are closely monitoring upcoming corporate earnings reports from several high-profile companies.

D-St set for a positive opening as GIFT Nifty signals firm start
On Thursday, market indices Nifty and Sensex experienced notable advances, illustrating a surge in local investor confidence. The Nifty surpassed the 23,000 mark, buoyed by strong domestic demand and robust tax revenue. Experts predict that the market may undergo a period of consolidation amid recovery efforts and selling pressures. While foreign portfolio investors engaged in net selling, domestic institutions stepped up as net buyers.

US Stock Market: What to led to S&P 500, Nasdaq, Dow Jones, Russell 2000 rebound after historic low despite fall of Nvidia stocks, TSMC shares?
US Stock Market today: Nvidia dipped 1.8 per cent after chip manufacturer TSMC struck a cautious note on 2027 despite reporting a sixth consecutive record quarterly profit on robust AI-driven demand.

US stocks: Dow, S&P 500 end higher as traders shift from AI to healthcare
After a rocky start, the S&P 500 experienced a resurgence, largely spurred by investments in the healthcare and consumer segments. Investors seemed to distance themselves from technology stocks, anxious about mounting debts in the AI sector. Eli Lilly and UnitedHealth rose thanks to favorable evaluations from Deutsche Bank, whereas Broadcom and Nvidia struggled.

AstraZeneca strikes $40 million AI drug discovery deal with insitro
AstraZeneca has entered a collaboration with insitro to explore new treatment options for challenging liver and heart diseases. The partnership involves a $40 million upfront payment and potential milestones totaling approximately $1.46 billion. Insitro will utilize its AI platform to identify biological drivers for metabolic dysfunction-associated steatohepatitis and cardiomyopathies. Following this, AstraZeneca will manage clinical trials and further development. This collaboration signifies insitro's growing presence in the pharmaceutical industry.

AstraZeneca strikes $40 million AI drug discovery deal with insitro
AstraZeneca has entered into a partnership with insitro to identify treatments for challenging liver and heart diseases. This collaboration, which involves a $40 million upfront payment, could reach $1.46 billion in total milestones. The companies aim to tackle metabolic dysfunction-associated steatohepatitis and cardiomyopathies through insitro's AI platform.

MacKenzie Scott never forgot her college roommate's $1,000 help, a dentist's free treatment. Years later, ex-wife of Jeff Bezos gave away $26 billion in philanthropy
MacKenzie Scott's journey began with hardships at Princeton University, where she was uplifted by her friends' support. Following her separation from Jeff Bezos, she transformed into a celebrated novelist and philanthropist. Dedicated to philanthropy, she pledges to give away half of her fortune, fueled by her belief in the power of generosity. Having donated over $26 billion, she targets vital areas like education and economic recovery.

Assessing products to counter side effects of GLP-1, says Bayer's Triana
Bayer AG plans to expand its consumer health business in India significantly by 2030. The company aims to triple its revenue in the Indian market during this period. Bayer is specifically targeting opportunities in digestive health, nutrition, and multivitamins related to GLP-1 drug side effects. Additionally, Bayer will develop products locally and seek manufacturing partnerships to enhance their market presence.

Our central mission must be patient-centric innovation: JP Nadda
J P Nadda urges industry to take discoveries ‘from bench to bedside’ as the FICCI–Lilly Bharat Life Sciences Award backs its inaugural cohort with ₹7 crore in grants
Load More